Addus HomeCare heads into today's earnings print with the most extreme options defensive posture it has seen in the past year.
The options signal dominates the setup. The put/call ratio hit 4.36 on Monday — three standard deviations above its 20-day average of 0.55, and the highest reading of the past 52 weeks. That is not routine hedging. For a stock with a relatively small options market, a ratio that far above normal points to concentrated demand for downside protection in the immediate run-up to the print. The stock itself has climbed 11% over the past month to close at $116.79, and edged up another 1.1% on Monday, so this protective positioning is not a reaction to price weakness — it is a deliberate earnings hedge laid on top of a recent rally.
Short interest tells a different story, and the contrast matters. Bears have been building positions rapidly — SI jumped nearly 20% in a single week to reach 7.2% of the free float, the highest it has been in the trailing month. But the borrow market is nowhere near stressed. Availability remains extremely loose at 723%, meaning there are roughly seven shares available to lend for every one already borrowed. Cost to borrow is negligible at 0.55%. Short sellers have piled in, but they face no squeeze pressure whatsoever — the lending pool is deep and cheap.
The fundamental debate cuts along familiar lines in home health care. Bulls point to Addus's three-segment structure, a credible M&A pipeline, and recent Indiana market expansion. The company has delivered a five-year EBIT CAGR of 21% and carries a Piotroski F-score of 8, signalling strong underlying quality. Bears centre their concern on Medicaid and Medicare reimbursement risk — a perennial issue for the sector — and labor cost constraints that cap margin expansion. The analyst community reflects this split: Barclays has maintained an Underweight rating throughout 2026, most recently raising its target to $96 in July, well below the current price of $116.79. The bull side is anchored by Citizens and Stephens, with targets in the $135–$142 range. The consensus mean of $133.54 implies modest upside from current levels, but Barclays' bear case is already in the money on the downside.
BlackRock holds 16.9% of shares and added 281,200 shares as of June 30, a meaningful vote of confidence heading into the print. Insider activity over the past 90 days has been exclusively small-scale selling — sub-$50,000 per trade across mid-level executives — with no offsetting buying, a modest cautionary note though the amounts are insignificant relative to the float.
The print will test whether Addus's personal care and hospice segments are growing fast enough to justify a stock trading well above the most bearish target on the Street, even as short sellers load up and options traders demand the most downside protection they have all year.
See the live data behind this article on ORTEX.
Open ADUS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
